Stock Detail
AVI BIOPHARMA INC
Biotechnology
AVII @ Yahoo Finance | AVII Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.88 | $0.91 | $0.01 | 1.15% | 0.00 | $0.87 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.86 | $0.86 | 594,766 | 119.45M | 1.15M | -11.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.93 | 0.90 | 0.88 | 0.85 | 0.83 |
Stock Profile
AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology. Its principal products in development target life-threatening diseases, including cardiovascular disease, infectious disease, and cancer. AVI's lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the re-narrowing of a coronary artery following angioplasty. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single–stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease. The company has strategic alliances with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was incorporated in 1980 as Antivirals, Inc. and changed its name to AVI BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.